Achilles Torn wrote:Grouseman. Sorry to hear about your wife's recent blockage. I hope things are getting better.
This is an interesting trial to me as well. You mention ERRB pathways to get around EGFR inhibition. That interests me as I have ERRB4 mutation. Did the paper you read indicate having such a mutation would make EGFR inhibitors ineffective so maybe not the trial for me ?
Well - I went looking for the paper again and couldn't find it in any of my saved web pages about EGFr inhibitors which is one of the anticancer drug candidates I worked on (dacomitinib) in some of its early synthetic stages. It will likely depend on the ERBB4 mutation. The particular EGFr inhibitor in this study is Erbitux (Cetuximab) a Monoclonal antibody, that binds to the surface EGFr protein - I am not sure of the specific binding site. But generally its not usually the ATP binding pocket like small molecule EGFr inhibitors bind. I don't know to what extent the antibody binds to other ERbb family members. Probably non at all.
The mutation you have they may not know if its driving your cancer or not. But I suspect that if it is the Erbitux will not bind to it anyway. You would need a different EGFr inhibitor that binds both EGFr and ERBB4. Wouldn't hurt if it also bound to the others Erbb2, 3 as well. Dacomitinib does bind EGFr, Erbb2 and Erbb4.
Here is a link about Erbb4: https://en.wikipedia.org/wiki/ERBB4
another about Dacomitinib: http://pubs.acs.org/doi/abs/10.1021/bk-2016-1239.ch008
It never hurt to ask the Clinical Trial manager if you qualify or not.
If I could create a clinical trial similar to this I would elect to use Dacomitinib + Keytruda instead.